Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of ENN0403 in Healthy Adults
NCT05506540Phase 1Completed
- Sponsor
- EnnovaBio
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ENN0403 in Nonalcoholic steatohepatitis (NASH), diabetic retinopathy (DR) and pulmonary fibrosis (PF) (10 arms), sponsored by EnnovaBio. Primary endpoint: Number of participants with treatment emergent adverse events. Started Feb 2021; status: completed.
02
Drugs
ENN0403
03
Conditions
Nonalcoholic steatohepatitis (NASH)diabetic retinopathy (DR)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05506540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506540.